1. Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation
- Author
-
Daniel Rødbro Burmester, Martin Korsbak Madsen, Attila Szabo, Sagar Sanjay Aripaka, Dea Siggaard Stenbæk, Vibe G. Frokjaer, Betina Elfving, Jens D. Mikkelsen, Gitte Moos Knudsen, and Patrick MacDonald Fisher
- Subjects
Psilocybin ,Inflammation ,Neuroinflammation ,Biomarkers ,Psychedelics ,Immune system ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Psychology ,BF1-990 - Abstract
Rationale: Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonergic psychedelics, have anti-inflammatory effects. This may contribute to its therapeutic effects as previous studies indicate a link between neuropsychiatric disorders and inflammatory processes. However, the effect of psilocybin on biomarkers of inflammation has not been evaluated in humans. Objectives: Investigate the effect of a single dose of psilocybin on peripheral biomarkers of inflammation in healthy humans. Methods: Blood samples were collected from 16 healthy participants before and one day after the administration of a single oral dose of psilocybin (mean dose: 0.22 mg/kg) and subsequently analyzed for concentrations of high-sensitivity C-reactive protein (hsCRP), tumor-necrosis-factor (TNF) and soluble urokinase plasminogen activator receptor (suPAR). Change in inflammatory markers was evaluated using a paired t-test where p
- Published
- 2023
- Full Text
- View/download PDF